# Fermi Inc

Type: Company (FRMI)

Source: GetYourBrief — https://getyourbrief.com/entity/fermi-inc
Canonical HTML page: https://getyourbrief.com/entity/fermi-inc

## Timeline

- **2026-Q3**: Motion to Dismiss Phase — Defendants expected to file motions to dismiss based on Safe Harbor protections for forward-looking statements.
- **2026-04-15**: Lead Plaintiff Deadline — Estimated deadline for investors to file motions to be appointed as lead plaintiff in the respective cases.
- **2026-04-15**: Lead Plaintiff Deadline (Est.) — Typical 60-day window for investors to petition the court to lead the consolidated class action.
- **2026-03-06**: Market Reaction — Investors and analysts begin assessing the potential litigation overhang on RARE, MREO, FRMI, and NAVN.
- **2026-03-05**: Investor Alerts Issued — Pomerantz Law Firm releases simultaneous reminders for class action lawsuits against four companies.
- **2026-03-05**: Investor Alerts Issued — Pomerantz Law Firm releases multiple reminders for class action deadlines across the biotech sector.

## Recent coverage (2 stories, network-wide)

### Pomerantz Law Firm Issues Class Action Deadlines for Major Biotech Firms
2026-03-05 23:21:15 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 4

Pomerantz Law Firm has issued urgent reminders to investors regarding class action deadlines for Ultragenyx, Mereo BioPharma, Navan, and Fermi. These legal actions follow allegations of misleading statements and failures to disclose material risks concerning clinical data and financial projections.
Full story: https://getbiobrief.com/story/pomerantz-biotech-class-action-deadlines-2026

### Pomerantz Law Firm Targets Biotech and Tech Sectors in Securities Class Actions
2026-03-05 23:21:10 · Sector: legal · Sentiment: Neutral · Impact: 5/10 · Sources: 4

Pomerantz Law Firm has issued a series of investor alerts regarding class action lawsuits against Ultragenyx Pharmaceutical, Fermi Inc., Mereo BioPharma, and Navan, Inc. These filings highlight a surge in securities litigation targeting volatility in the biotechnology and emerging technology sectors, emphasizing critical lead plaintiff deadlines for affected shareholders.
Full story: https://getlegalbrief.com/story/pomerantz-securities-class-actions-biotech-tech-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.